Free Trial

MacroGenics (MGNX) Stock Forecast & Price Target

$5.33
-0.01 (-0.19%)
(As of 07/23/2024 ET)

MacroGenics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 10 Wall Street analysts who have issued ratings for MacroGenics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 10 analysts, 4 have given a hold rating, and 6 have given a buy rating for MGNX.

Consensus Price Target

$12.00
125.14% Upside
High Forecast$25.00
Average Forecast$12.00
Low Forecast$4.00

According to the 10 analysts' twelve-month price targets for MacroGenics, the average price target is $12.00. The highest price target for MGNX is $25.00, while the lowest price target for MGNX is $4.00. The average price target represents a forecasted upside of 125.14% from the current price of $5.33.

TypeCurrent Forecast
7/24/23 to 7/23/24
1 Month Ago
6/24/23 to 6/23/24
3 Months Ago
4/25/23 to 4/24/24
1 Year Ago
7/24/22 to 7/24/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
6 Buy rating(s)
7 Buy rating(s)
6 Buy rating(s)
Hold
4 Hold rating(s)
4 Hold rating(s)
1 Hold rating(s)
4 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$12.00$12.00$17.00$12.11
Forecasted Upside125.14% Upside45.77% Upside35.08% Upside92.58% Upside
Get MacroGenics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for MGNX and its competitors with MarketBeat's FREE daily newsletter.

MGNX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

MGNX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

MacroGenics Stock vs. The Competition

TypeMacroGenicsMedical CompaniesS&P 500
Consensus Rating Score
2.60
2.72
2.51
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside125.14% Upside3,059.01% Upside9.72% Upside
News Sentiment RatingNeutral News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/24/2024BTIG Research
2 of 5 stars
 Lower TargetBuy ➝ Buy$24.00 ➝ $9.00+95.23%
5/13/2024HC Wainwright
3 of 5 stars
R. Burns
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetNeutral ➝ Neutral$16.00 ➝ $4.00-5.66%
5/10/2024Barclays
2 of 5 stars
 Lower TargetOverweight ➝ Overweight$25.00 ➝ $14.00+320.42%
5/10/2024JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetMarket Outperform ➝ Market Outperform$22.00 ➝ $16.00+353.26%
5/10/2024BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
E. Darout
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform$24.00 ➝ $8.00-45.47%
5/10/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$29.00 ➝ $7.00-52.28%
5/10/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
4/26/2024B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$25.00+73.97%
12/20/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$7.00 ➝ $13.00+40.85%
11/7/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$12.00+120.59%
11/22/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform
8/9/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$15.00 ➝ $12.00+137.62%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 11:06 PM ET.

MGNX Forecast - Frequently Asked Questions

What is MacroGenics' forecast for 2024?

According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for MacroGenics is $12.00, with a high forecast of $25.00 and a low forecast of $4.00.

Should I buy or sell MacroGenics stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MacroGenics in the last year. There are currently 4 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" MGNX shares.

Does MacroGenics's stock price have much upside?

According to analysts, MacroGenics's stock has a predicted upside of 45.77% based on their 12-month stock forecasts.

Has MacroGenics been downgraded by Wall Street analysts recently?

Over the previous 90 days, MacroGenics's stock had 3 downgrades by analysts.

What analysts cover MacroGenics?

MacroGenics has been rated by research analysts at B. Riley, Barclays, BMO Capital Markets, BTIG Research, HC Wainwright, JMP Securities, Stifel Nicolaus, and TD Cowen in the past 90 days.

Do Wall Street analysts like MacroGenics more than its competitors?

Analysts like MacroGenics less than other "medical" companies. The consensus rating score for MacroGenics is 2.60 while the average consensus rating score for "medical" companies is 2.72. Learn more on how MGNX compares to other companies.


This page (NASDAQ:MGNX) was last updated on 7/23/2024 by MarketBeat.com Staff

From Our Partners